Trading Signals: SNGX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Fri. Oct. 21, 2016)(Soligenix, Inc.)
| SNGX latest price $112.0000 (-1.75%) ($106.0000 - $114.0000) on Fri. Jun. 25, 2004. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 4.3% (three month average) | | RSI | 44 | | Latest Price | $112.0000(-1.75%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | SNGX declines -1.3% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support SNGX advance at 0% a week (0% probability)
OIH(10%) QQQ(7%) IWM(6%) SPY(6%) XLK(6%) | | Factors Impacting SNGX price | SNGX will decline at least -2.15% in a week (0% probabilities).
TLT(-6%) SHY(-3%) TIP(-1%) LQD(-1%) REMX(-0%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.15% (StdDev 4.3%) | | Hourly BBV | 0 () | | Intraday Trend | -1.8% | | | | | |
|
| Resistance Level | $117.92 | | 5 Day Moving Average | $117.6(-4.76%) | | 10 Day Moving Average | $117.02(-4.29%) | | 20 Day Moving Average | $117.92(-5.02%) | | To recent high | -41.1% | | To recent low | 0% | | Market Cap | $3.202b | | | | | | |
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.March 23, 2020 On March 23, 2020, Soligenix, Inc. (NASDAQ:SNGX) announced an expansion of the ongoing collaboration with the University of Hawaii at Manoa to develop potential coronavirus vaccines, including one against SARS-CoV-2 to prevent COVID-19. Soligenix has performed extensive work on vaccines targeting other viruses in collaboration with the University of Hawaii, the University of Colorado, and Hawaii Biotech, Inc. That work has demonstrated efficacy in using a surface protein from other viruses (e.g., ebola), adjuvanting them, and thermostabilizing them. SARS-CoV-2, and other betacoronaviruses, have spike proteins on the surface that aids in viral entry and antibodies to that protein could prevent viral entry. |